第二类限制性股票授予价格：10.15 元/股； 第二类限制性股票归属股票来源：公司向激励对象定向发行公司 A 股普 通股股票； 本次归属的限制性股票在相关手续办理完后、上市流通前，公司将发布 相关提示性公告，敬请投资者注意。 证券代码：300887 证券简称：谱尼测试 公告编号：2024-042 谱尼测试集团股份有限公司 关于 2021 年限制性股票激励计划首次授予部分 第一类激励对象第二个归属期归属条件成就的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 本次符合第二类限制性股票归属条件的激励对象共计 277 人； 第二类限制性股票拟归属数量为 742,671 股，占目前公司股本总额的 0.1360%； （三）本激励计划的归属安排 本激励计划授予的第二类限制性股票在激励对象满足相应归属条件后将按 约定比例分次归属，归属日必须为交易日，且获得的第二类限制性股票不得在下 列期间内归属： 1、公司年度报告、半年度报告公告前三十日内，因特殊原因推迟公告日期 的，自原预约公告日前三十日起算； 谱尼测试集团股份有限公司（以下简称"公司"）于 202 ...

证券代码：300887 证券简称：谱尼测试 公告编号：2024-037 谱尼测试集团股份有限公司 2023 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 特别提示： 通过深圳证券交易所交易系统进行网络投票的时间为 2024 年 5 月 15 日 9:15-9:25，9:30- 11:30 和 13:00-15:00。 通过深圳证券交易所互联网投票系统进行网络投票的时间为 2024 年 5 月 15 日上午 9:15 至下午 15:00 期间的任意时间。 3、会议召开地点：北京市海淀区中关村环保科技示范园锦带路 66 号院 1 号楼谱尼测试大 厦公司 207 会议室。 4、会议召开方式：现场表决与网络投票相结合 5、会议召集人：公司董事会 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开情况 1、谱尼测试集团股份有限公司（以下简称"公司"）2023 年度股东大会通知于 2024 年 4 月 23 日在中国证监会指定信息披露网站巨潮资讯网（http://www.cninfo.com. ...

关于回购注销部分限制性股票减少注册资本 暨通知债权人的公告 证券代码：300887 证券简称：谱尼测试 公告编号：2024-038 谱尼测试集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 谱尼测试集团股份有限公司（以下简称"公司"）于 2024 年 4 月 22 日召开了第五届董事 会第十次会议和第五届监事会第九次会议，审议通过《关于回购注销部分已获授但尚未解锁的 限制性股票的议案》，鉴于： 1、公司 2021 年限制性股票激励计划（以下简称"本激励计划""激励计划"）中授予的 36 名激励对象（其中首次授予部分 31 人，预留授予部分 5 人）因个人原因已离职，不再 具备激励对象资格，公司将其持有的已获授但尚未解除限售的限制性股票 67,742 股进行 回购注销。 2、公司 2021 年限制性股票激励计划中 2023 年度业绩未达到业绩考核目标，董事会同意 公司将其首次及预留的第三个解除限售期不能解除限售的 256,381 股第一类限制性股票 回购注销。 上述议案已经公司 2023 年度股东大会审议通过。 本次部分限制性股票回购注销完成后 ...

北京德恒律师事务所 法律意见 关于谱尼测试集团股份有限公司 北京德恒律师事务所 2023 年度股东大会的法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话:010-52682888 传真:010-52682999 邮编:100033 北京德恒律师事务所 关于 谱尼测试集团股份有限公司 2023 年度股东大会的 法律意见 德恒 01G20200488-17 号 为出具本法律意见，本所律师审查了公司本次股东大会的有关文件和材料，同 时本所律师出席本次股东大会会议，依法参与了现场参会人员身份证明文件的核验 工作，见证了本次股东大会召开、表决和形成决议的全过程。 在本法律意见中，本所律师仅对本次股东大会的召集、召开程序、出席会议人 员资格、召集人资格及会议表决程序、表决结果是否符合《公司法》《股东大会规 则》等法律、法规、规范性文件及《公司章程》的规定发表意见，不对会议审议的 议案内容以及该等议案所表述的事实或数据的真实性及准确性发表意见。 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》和 《律师事务所证券法律业务执业规则（试行）》等规定及本法律意见出具日以前已 经发生或者存在 ...

华泰联合证券有限责任公司 关于谱尼测试集团股份有限公司 2023 年度持续督导跟踪报告 | 保荐人名称：华泰联合证券有限责任公司 | 被保荐公司简称：谱尼测试集团股份有限公司 | | --- | --- | | 保荐代表人姓名：刘晓宁 | 联系电话：010-56839300 | | 保荐代表人姓名：王禹 | 联系电话：010-56839300 | 一、保荐工作概述 1 | 项目 | 工作内容 | | --- | --- | | （2）发表非同意意见所涉问题及结论意见 | 无 | | 7.向深圳证券交易所报告情况（现场检查报 | | | 告除外） | | | （1）向深圳证券交易所报告的次数 | 无 | | （2）报告事项的主要内容 | 不适用 | | （3）报告事项的进展或者整改情况 | 不适用 | | 8.关注职责的履行情况 | | | （1）是否存在需要关注的事项 | 是 | | | 公司于2024年 1月 24日收到了中国证券 | | | 监督管理委员会北京监管局下发的《关于对谱 | | | 尼测试集团股份有限公司、宋薇、张英杰、刘 | | | 永梅、李小冬出具责令改正行政监管措施的决 | | | 定》 ...

保荐总结报告书 华泰联合证券有限责任公司 关于谱尼测试集团股份有限公司 首次公开发行股票并在创业板上市 之保荐总结报告书 | 保荐机构名称 | 华泰联合证券有限责任公司 | | --- | --- | | 保荐机构编号 | Z26774000 | 一、保荐机构及保荐代表人承诺 1、保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误导 性陈述或重大遗漏，保荐机构及保荐代表人对其真实性、准确性、完整性承担法 律责任。 2、本机构及本人自愿接受中国证券监督管理委员会（以下简称"中国证监 会"）、深圳证券交易所对保荐总结报告书相关事项进行的任何质询和调查。 3、本机构及本人自愿接受中国证监会按照《证券发行上市保荐业务管理办 法》的有关规定采取的监管措施。 二、保荐机构基本情况 | 情况 | 内容 | | --- | --- | | 保荐机构名称 | 华泰联合证券有限责任公司 | | 注册地址 | 深圳市前海深港合作区南山街道桂湾五路 128 号前海深港基金小 | | | 镇 B7 栋 401 | | 主要办公地址 | 北京市西城区丰盛胡同 22 号丰铭国际大厦 A 座 6 层 | | 法定代表人 | 江禹 ...

Financial Performance - In 2023, the company achieved operating revenue of 2.468 billion yuan and a net profit attributable to shareholders of 108 million yuan [2] - The net cash flow from operating activities was 328 million yuan [2] - In Q1 2024, the company reported operating revenue of 334 million yuan [2] Business Development - The company focused on inspection and testing, leveraging technology for high-quality development [2] - Significant investments were made in biomedicine, new energy vehicles, and special industry testing, which require time for market expansion [2] - The company plans to continue cost reduction and efficiency improvement measures to enhance operational efficiency and management levels [2] Industry Positioning - The automotive testing business showed steady growth in 2023 and continued in Q1 2024, supported by multiple qualifications and participation in national standards formulation [2][3] - The company has established partnerships with over 60 automotive brands and new car manufacturers [3] Future Plans - The company aims to enhance its biomedicine CRO/CDMO business and accelerate investment in medical device testing [2] - The Shanghai laboratory for new energy and energy storage batteries was officially put into operation in November 2023, equipped with advanced testing facilities [3] - The company is cautious about future capital expenditures, considering capacity utilization and industry mergers [4] Cost Management - The company is building an information system for transparent and efficient operations and is exploring artificial intelligence for future efficiency gains [4] - Emphasis is placed on improving profit margins and cash flow through refined cost management [4]

Investment Rating - The report maintains an "Accumulate" rating for the company, indicating a positive outlook for the stock over the next 6 to 12 months [10][12]. Core Insights - The company's performance in 2023 was significantly impacted by a downturn in the medical testing sector, leading to a 34% year-on-year decline in total revenue to 2.5 billion yuan and a 67% drop in net profit to 108 million yuan [2][10]. - The first quarter of 2024 continued to show a decline, with total revenue of 330 million yuan, down 36% year-on-year, and a net loss of 98 million yuan, reflecting ongoing challenges in the medical testing segment [2][10]. - Despite short-term pressures, the company is expected to recover its profitability as the demand for medical testing stabilizes and operational efficiencies improve [12]. Financial Summary - Total revenue for 2023 was 2,468 million yuan, a decrease of 34.41% compared to the previous year, with a projected increase of 11.87% in 2024 [10][20]. - The net profit for 2023 was 107.78 million yuan, down 66.58% year-on-year, with expectations of a significant recovery to 302.05 million yuan in 2024 [10][20]. - The company's earnings per share (EPS) for 2023 was 0.20 yuan, with forecasts of 0.55 yuan in 2024 and 0.69 yuan in 2025 [10][20]. Business Segment Performance - The Life Sciences and Health Environmental segment generated 1.97 billion yuan in revenue, down 39% year-on-year, primarily due to reduced demand in infection-related services [2][12]. - The Automotive and Other Consumer Products segment saw a revenue decline of 10% to 260 million yuan, while the Safety Assurance segment's revenue fell by 16% to 130 million yuan [2][12]. - The Electronics and Electrical segment, however, experienced a 12% growth, reaching 79 million yuan [2][12]. Margin Analysis - The gross margin for 2023 improved to 42.8%, an increase of 7.2 percentage points year-on-year, while the net margin decreased to 4.4%, down 4.2 percentage points [2][12]. - The company’s operating expenses ratio was 32.3%, up 7.3 percentage points from the previous year, indicating a return to normal levels as the impact of the medical infection business diminishes [2][12]. Future Outlook - The company is positioned to benefit from the ongoing demand in low-altitude economy, special equipment, and marine pollution testing sectors, which are expected to drive future growth [12]. - The report anticipates a gradual recovery in revenue growth and profitability as the company optimizes its laboratory management and resource allocation [12].

Investment Rating - The report maintains a "Buy" rating for the company [17][15]. Core Views - The company experienced a significant decline in revenue and net profit in 2023, with revenue down 34.41% and net profit down 66.58% year-on-year. The first quarter of 2024 also saw a revenue decline of 36.36% and a net loss of 0.98 billion yuan [10][19]. - The report highlights expectations for a recovery in profitability in 2024, driven by improved management practices and a focus on high-margin business segments [10][15]. Summary by Sections Financial Performance - In 2023, the company reported total revenue of 24.68 billion yuan and a net profit of 1.08 billion yuan. The fourth quarter of 2023 saw revenue of 7.09 billion yuan, a decrease of 34.32% year-on-year, with net profit plummeting by 98.28% [19]. - The first quarter of 2024 showed a revenue of 3.34 billion yuan, a decline of 36.36%, and a net loss of 0.98 billion yuan compared to a profit of 0.09 billion yuan in the same period last year [19]. Business Segments - The life sciences and environmental health segment saw a revenue drop of 38.90% due to high base effects from the previous year and economic pressures affecting government spending [14]. - The automotive and other consumer goods segment reported a revenue decline of 10.44%, while the safety assurance segment decreased by 15.75% due to disruptions in the military sector [14]. - The electronics and electrical segment, however, experienced a revenue increase of 11.67%, indicating strong performance in specific areas [14]. Future Outlook - The report anticipates a revenue recovery in 2024, with expected revenues of 27.1 billion yuan, 30.5 billion yuan, and 34.1 billion yuan for 2024, 2025, and 2026 respectively. Net profit is projected to grow significantly, with a forecasted increase of 146.5% in 2024 [15][19]. - The company is expected to benefit from the release of revenue from environmental testing and the operational capacity of new automotive testing facilities [14][15].

证 券 研 究 报 告 | --- | --- | --- | |----------|----------------------|---------------------------| | | | ——谱尼测试 | | | 周天乐 ( 分析师 ) | 赵文通 ( 分析师 ) | | | 0755-23976003 | 010-83939799 | | | Zhoutianle@gtjas.com | zhaowentong026013@gtjas.c | | 证书编号 | S0880520010003 | om S0880524030001 | 本报告导读： | --- | --- | |----------------------------|--------------------| | | 资本货物 | | [Table_Invest 评级： ] | 增持 | | | 上次评级： 增持 | | 目标价格： | 14.10 | | | 上次预测： 18.75 | | 当前价格： | 10.44 | | | 2024.04.24 | 中 小 盘 研 究 减值影响短期业绩，持续并购构筑壁垒 中 小 盘 ...